Outlook therapeutics, inc. (OTLK)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
OPERATING ACTIVITIES
Net loss

-5,700

-16,602

-10,096

-4,440

-10,244

-9,741

-12,199

-8,431

-7,539

-1,920

-6,373

-5,331

-8,045

-19,098

-10,567

-22,327

-3,542

-16,864

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

176

175

888

833

816

823

824

822

731

676

670

672

680

669

603

598

598

593

Loss on extinguishment of debt

0

-8,060

-

-

-

-

0

0

0

-1,252

-

-

-

-

-

-

-

-

Non-cash interest expense

120

15

0

419

444

450

115

230

390

579

1,704

1,332

836

140

4

2

3

3

Stock-based compensation

304

359

204

-31

267

872

162

234

-300

1,889

1,658

2,121

2,327

2,464

3,831

10,574

-4,446

2,490

Change in fair value of redemption feature

-1,759

-37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-0

-201

-172

-1,931

1,301

-1,636

-821

64

-211

-78

817

-3,750

-1,035

810

-

-

-

-

Impairment of property and equipment

-

-

-

-

561

2,349

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-501

401

83

Prepaid expenses and other current assets

59

-288

433

2,740

20

50

813

343

-530

792

-328

274

-322

-2,230

2,067

546

-938

-142

Other assets

-32

115

-21

151

-20

-21

-35

-22

71

-14

-60

-18

-11

-21

-8

-21

-21

-5

Operating lease liability

-40

-39

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

738

290

599

-2,164

494

-260

1,287

-1,092

40

-6,949

-934

-311

1,074

5,898

382

-7,587

2,112

-233

Accrued expenses

-1,339

1,105

606

-311

640

-1,419

436

482

-24

-2,559

-502

203

-26

1,220

-2,132

3,130

-2,046

2,203

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

50

50

Deferred revenue

-

-

-5,868

-583

-641

-1,052

-771

-741

-771

-771

2,097

-303

-303

-303

-494

-494

-494

-494

Other liabilities

20

28

21

294

-84

-137

-326

217

-211

-10

-7

-8

48

103

57

85

136

176

Net cash used in operating activities

-7,083

-6,673

-5,916

-10,332

-6,259

-9,781

-8,394

-8,535

-7,438

-8,671

-

-

-

-

-

-

-

-

INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,110

-5,841

-10,370

-16,041

-7,058

-12,012

Purchase of property and equipment

-

-

0

150

50

236

1,262

168

275

1,075

23

76

43

148

328

452

-46

364

Net cash used in investing activities

-

-

-0

-150

-50

-236

-1,262

-168

-275

-1,075

-

-

-

-

-

-

-

-

FINANCING ACTIVITIES
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-43

-148

-328

-452

46

-364

Proceeds from the sale of common stock, net of offering costs

-

-

0

26,156

7,922

11,885

-

-

-

-

-

-

-

-

0

0

4,819

11,318

Payment of debt issuance costs

-

-

-

-

-

-

-

-

-

-

0

0

0

40

-

-

-

-

Proceeds from subscriptions receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,280

Proceeds from issuance of Series A convertible preferred stock

-

-

-

-

-

-

-

-

0

21,737

-

-

-

-

-

-

-

-

Proceeds from the sale of senior secured notes and detachable warrants

-

-

-

-

-

-

-

-

-

-

0

5,000

1,650

8,350

-

-

-

-

Proceeds from future stock issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

Proceeds from exercise of common stock warrants

1,080

58

-

-

-

-

-

-

-

-

0

130

119

3

-

-

-

-

Payments of finance lease obligations

123

55

-

-

184

231

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of stockholder notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,040

487

6,073

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

0

0

-216

-

-

-

-

Payments of capital leases obligations

-

-

-

-

-

-

228

259

155

219

261

252

244

232

225

216

220

222

Repayment of debt

11

11

13

1,777

1,500

3,126

33

32

31

30

12

37

48

2,579

507

186

184

180

Payment of financing costs

-

-

-

-

-

-

-

0

0

1,089

-

-

-

-

-

-

-

-

Net cash provided by financing activities

10,402

-8

-68

24,328

6,237

8,528

-422

14,563

-187

20,398

-

-

-

-

-

-

-

-

Net decrease in cash

3,319

-6,681

-

-

-72

-1,489

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from related party receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43

-0

595

187

Deconsolidation of Sonnet Biotherapeutics, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

401

Payment of employee tax withholdings related to the vesting of restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

71

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

2,156

5,716

-504

27,207

4,271

8,887

Net increase in cash

-

-

-

-

-

-

-

5,860

-7,901

10,652

3,045

58

-1,997

-273

-11,203

10,713

-2,740

-3,488

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

197

221

-

706

387

407

Cash paid for interest

357

360

84

1,028

24

1,657

28

55

0

25

-

-

-

-

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2

Supplemental schedule of noncash investing activities:
Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

-46

469

625

-

435

-62

90

-

-55

58

20

-

-

-

-

Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-158

836

-200

Supplemental schedule of noncash financing activities:
Unsecured notes and accrued interest converted into common stock

0

-1,548

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of exchange notes at estimated fair value

0

7,050

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of redemption feature at estimated fair value

0

8,264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

493

1,030

939

Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,816

157

2,671

-2,749

Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount

-

-

-

-

-

-

-

0

0

1,409

-

-

-

-

-

-

-

-

Issuance of common and Series A preferred stock to redeemable preferred stockholders and noncontrolling interests upon reincorporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

23,789

-11,894

Reclassification of equity classified stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

15,118

Change in fair value of convertible senior secured notes warrants recorded as debt discount

-

-

0

0

0

1,466

-

-

-

-

-

-

-

-

-

-

-

-

Series A-1 convertible preferred stock dividends and related settlement

0

166

-

-

154

150

-

-

-

-

-

-

-

-

-

-

-

-

Series A and A-1 convertible preferred stock dividends

-

-

-

-

-

-

-

-451

653

450

-

-

-

-

-

-

-

-

Deferred offering costs and common stock issuance costs in accounts payable and accrued expenses

-

-

-

-

0

74

-

-

-

-

923

-581

151

137

-

-1,093

2,126

-1,014

Accrued directors' fees settled in fully vested stock options

-

-

0

0

0

49

-

-

-

-

-

-

-

-

-

-

-

-